Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)’s share price fell 0.8% on Friday . The stock traded as low as $42.04 and last traded at $42.78, with a volume of 337,336 shares changing hands. The stock had previously closed at $43.14.

A number of equities analysts recently commented on the company. Mizuho reiterated a “buy” rating and set a $71.00 price target on shares of Eagle Pharmaceuticals in a report on Friday, May 6th. Piper Jaffray Cos. reduced their price target on Eagle Pharmaceuticals from $121.00 to $98.00 and set an “overweight” rating for the company in a report on Friday, March 18th. Royal Bank Of Canada reiterated a “buy” rating and set a $78.00 price target on shares of Eagle Pharmaceuticals in a report on Monday, June 13th. Finally, Zacks Investment Research upgraded Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, July 4th. Two analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $88.94.

The stock has a 50 day moving average price of $43.77 and a 200 day moving average price of $53.82. The stock’s market capitalization is $668.91 million.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings data on Monday, May 9th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $0.46 by $0.52. The firm had revenue of $29.60 million for the quarter, compared to analysts’ expectations of $29.07 million. The company’s revenue for the quarter was down 18.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.31 EPS. On average, equities analysts expect that Eagle Pharmaceuticals Inc. will post $4.16 EPS for the current year.

In other news, major shareholder Proquest Management Llc sold 17,980 shares of the company’s stock in a transaction dated Friday, May 13th. The shares were sold at an average price of $40.72, for a total transaction of $732,145.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Other large investors have bought and sold shares of the company. ProShare Advisors LLC acquired a new stake in Eagle Pharmaceuticals during the fourth quarter worth $1,222,000. California State Teachers Retirement System raised its stake in Eagle Pharmaceuticals by 1.3% in the fourth quarter. California State Teachers Retirement System now owns 15,870 shares of the specialty pharmaceutical company’s stock worth $1,407,000 after buying an additional 200 shares in the last quarter. Turner Investments L.P. acquired a new stake in Eagle Pharmaceuticals during the fourth quarter worth $2,350,000. Morgan Stanley raised its stake in Eagle Pharmaceuticals by 192.4% in the fourth quarter. Morgan Stanley now owns 47,523 shares of the specialty pharmaceutical company’s stock worth $4,213,000 after buying an additional 31,273 shares in the last quarter. Finally, EAM Investors LLC raised its stake in Eagle Pharmaceuticals by 16.2% in the fourth quarter. EAM Investors LLC now owns 48,624 shares of the specialty pharmaceutical company’s stock worth $4,311,000 after buying an additional 6,780 shares in the last quarter.

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care, orphan diseases and oncology areas. Its commercial products include Argatroban Injection, Ryanodex (dantrolene sodium) for injectable suspension, Diclofenac sodium misoprostol and Docetaxel Injection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.